Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.

PloS one - 1 Jan 2013

Barosi Giovanni, Poletto Valentina, Massa Margherita, Campanelli Rita, Villani Laura, Bonetti Elisa, Viarengo Gianluca, Catarsi Paolo, Klersy Catherine, Rosti Vittorio

Abstract excerpt

PURPOSE: The influence of JAK2 V617F mutation on blast transformation (BT) and overall survival (OS) in primary myelofibrosis (PMF) is controversial. In a large cohort of patients we applied competing risks analysis for studying the influence of JAK2V617F mutation on BT in PMF. PATIENTS AND METHODS: In 462 PMF-fibrotic type patients (bone marrow [BM] fibrosis grade >0) we computed the incidence of BT and death in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Bone Marrow Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Homozygote

Share to Janus Kinase 2

Share to Primary Myelofibrosis

Share to Proportional Hazards Models

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23555782
DOI: 10.1371/journal.pone.0059791
PMCID: PMC3608564

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.PMID 23555782Read ↗

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.Semantic proximity Read ↗

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.Semantic proximity Read ↗

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.Semantic proximity Read ↗

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.Semantic proximity Read ↗

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosisSemantic proximity Read ↗

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.Semantic proximity Read ↗

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.Semantic proximity Read ↗

Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells.Semantic proximity Read ↗

Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.Semantic proximity Read ↗

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.